U.S. Heparin Supplier Waited Nearly A Year Before Complaint Response
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA is still investigating an American company that sourced heparin from China that turned out to be contaminated with a deadly chemical; adulterated heparin triggered adverse reactions across U.S. hospitals two years ago